Autoimmunity and Liver Disease
1990; Lippincott Williams & Wilkins; Volume: 12; Issue: 2 Linguagem: Inglês
10.1002/hep.1840120225
ISSN1527-3350
AutoresKarl‐Hermann Meyer zum Büschenfelde, Ansgar W. Lohse, Michael P. Manns, Thomas Poralla,
Tópico(s)Diabetes and associated disorders
ResumoHepatologyVolume 12, Issue 2 p. 354-363 Special ArticleFree Access Autoimmunity and liver disease Prof. Dr. Dr. Karl-Hermann Meyer Zum Büschenfelde, Corresponding Author Prof. Dr. Dr. Karl-Hermann Meyer Zum Büschenfelde I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanyI. Med. Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 6500 Mainz 1, FRG===Search for more papers by this authorAnsgar W. Lohse, Ansgar W. Lohse I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanySearch for more papers by this authorMichael Manns, Michael Manns I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanySearch for more papers by this authorThomas Poralla, Thomas Poralla I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanySearch for more papers by this author Prof. Dr. Dr. Karl-Hermann Meyer Zum Büschenfelde, Corresponding Author Prof. Dr. Dr. Karl-Hermann Meyer Zum Büschenfelde I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanyI. Med. Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 6500 Mainz 1, FRG===Search for more papers by this authorAnsgar W. Lohse, Ansgar W. Lohse I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanySearch for more papers by this authorMichael Manns, Michael Manns I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanySearch for more papers by this authorThomas Poralla, Thomas Poralla I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, D-6500 Mainz, Federal Republic of GermanySearch for more papers by this author First published: August 1990 https://doi.org/10.1002/hep.1840120225Citations: 70AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Burnet FM. The clonal selection theory of acquired immunity. Nashville: Vanderbilt University Press, 1959. 2 Kisielow P, Blüthmann H, Staez UD, Steinmetz M, von Boehmer H. Tolerance in T-cell receptor transgenic mice involves deletion of nonmature CD4+ 8+ thymocytes. Nature 1988; 333: 742– 746. 3 Guilbert B, Dighiero G, Avrameas S. Naturally occurring antibodies against nine common antigens in normal humans. I. Detection, isolation, and characterization. J Immunol 1982; 28: 2779– 2787. 4 Cohen IR, Wekerle H. Autoimmunity, self-recognition, and blocking factors. In: N Talal, ed. Autoimmunity: genetic, immunologic, virologic, and clinical aspects. New York: Academic Press, 1977: 231– 243. 5 Schluesener HJ, Wekerle H. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. J Immunol 1985; 135: 3128– 3133. 6 Naparstek Y, Holoshitz J, Eisenstein S, Reshef T, Rappaport S, Chemeke S, Ben-Nun A, et al. Effector T lymphocyte line cells migrate to the thymus and persist there. Nature 1982; 300: 262– 263. 7 Goodnow CC, Crosbie J, Adelstein S, Laroie TB, Smith-Gill SJ, Brink RA, Prichard-Briscoe H, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocyte in transgenic mice. Nature 1988; 334: 676– 681. 8 Lohse AW. Autoreactive T-cells. Curr Opin Immunol 1989; 1: 718– 726. 9 Cohen IR. Regulation of autoimmune disease: physiological and therapeutic. Immunol Rev 1986; 94: 5– 21. 10 Lohse AW, Cohen IR. Experimental regulation of autoimmune disease. In: NR Farid, ed. Immunogenetics of autoimmune disease. New York: CRC Press [in press]. 11 Lider O, Reshef T, Beraud E, Ben-Nun A, Cohen IR. Antiidiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 1988; 239: 181– 183. 12 Lohse AW, Mor F, Karin N, Cohen IR. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 1989; 244: 820– 822. 13 Cohen IR, Cooke A. Natural autoantibodies might prevent autoimmune disease. Immunol Today 1986; 7: 363– 364. 14 Miller MH, Krowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. QJ Med 1984; 53: 401– 409. 15 Mills PR, Sturrock RD. Clinical association between arthritis and liver disease. Ann Rheum Dis 1982; 41: 295– 307. 16 Runyon BA, La Brecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Am J Med 1980; 69: 187– 194. 17 Carneskog J, Florath-Ahlman M, Olsson R. Prevalence of liver disease in patients taking salicylates for arthropathy. Hepatogastroenterology 1980; 27: 361– 364. 18 Holdstock G, Millward-Sadler GH, Wright R. Hepatic changes in systemic disease. In: R Wright, Millward- GH Sadler, KGMM Alberti, S Karran, eds. Liver and biliary disease. London: WB Saunders 1985: 1033– 1076. 19 Calne RY, Davis DR, Hadiyannakis D. Immunosuppressive effects of soluble cell membrane fractions, donor blood and serum on renal allograft survival. Nature 1970; 227: 903– 906. 20 Addison T, Gull W. On a certain affection of the skin: vitiligoidea alpha plana, beta tuberosa. Guy's Hosp Rep 1851; 7: 265– 276. 21 Ahrens EH Jr, Payne MA, Kunkel HG. Primary biliary cirrhosis. Medicine 1950; 29: 299– 336. 22 Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis: chronic non-suppurative destructive cholangitis. Am J Pathol 1965; 46: 387– 407. 23 Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257– 1260. 24 Sherlock S. Primary biliary cirrhosis: critical evaluation and treatment policies. Scand J Gastroenterol Suppl 1982; 77: 63– 74. 25 James O, Macklon AF, Watson AJ. Primary biliary cirrhosis: a revised clinical spectrum. Lancet 1981; 1: 1278– 1280. 26 Rolls J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1– 7. 27 Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis. Gastroenterology 1985; 89: 267– 271. 28 Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1987; 316: 521– 528. 29 James SP, Hoofnagle JH, Strober W, Jones EA. Primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med 1983; 99: 500– 512. 30 Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57: 365– 70. 31 Waldenström J. Leber, Blutproteine und Nahrungseiweiß. Dtsch Z Verdau Stoffwechselkr 1950; 15: 113– 116. 32 Kunkel HG, Ahrens EH Jr, Eisenmenger WJ. Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology. J Clin Invest 1951; 30: 654– 659. 33 Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis. Lancet 1956; 2: 1323– 1326. 34 Read AE, Sherlock S, Harrison CV. Active "juvenile" cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy. Gut 1963; 4: 378– 393. 35 Holdstock G, Rassam S, Millward-Sadler GH, Wright R. Different aetiology of chronic active hepatitis in UK and Iraq. Liver 1983; 3: 2– 7. 36 Maddrey WC. Subdivision of idiopathic autoimmune chronic active hepatitis. Hepatology 1987; 7: 1372– 1374. 37 Manns M. Autoantibodies and antigens in liver diseases-updated. J Hepatol 1989; 9: 272– 280. 38 Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khadil SH, Poupon R, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333– 1339. 39 Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K-H. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292– 294. 40 Biorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley CD. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512– 518. 41 Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in the diagnosis of primary biliary cirrhosis. Lancet 1965; 1: 827– 831. 42 Doniach D, Roitt IM, Walker JG, Sherlock S. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol 1966; 1: 237– 262. 43 Klatskin G, Kantor FS. Mitochondrial antibodies in primary biliary cirrhosis and other diseases. Ann Intern Med 1972; 11: 533– 541. 44 Munoz LE, Thomas HC, Scheuer PJ, Doniach D, Sherlock S. Is mitochondrial antibody a diagnostic marker of primary biliary cirrhosis? Gut 1981; 2: 136– 140. 45 Berg PA, Klein R, Lindenborn-Fotinos J, Kloppel W. ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet 1982; 2: 1423– 1425. 46 Manns M, Gerken G, Kyriatsoulis A, Trautwein C, Reske K, Meyer zum Büschenfelde K-H. Two different subtypes of antimitochondrial antibodies are associated with primary biliary cirrhosis: identification and characterization by radioimmunoassay and immunoblotting. Hepatology 1987; 7: 893– 899. 47 Berg PA, Klein R, Lindenborn-Fotinos J. Antimitochondrial antibodies in primary biliary cirrhosis. J Hepatol 1986; 2: 123– 131. 48 Berg PA, Wiedmann KH, Sayers T, Klöppel G, Lindner H. Serological classification of chronic cholestatic liver disease by the use of two different types of anti-mitochondrial antibodies. Lancet 1980; 2: 1329– 1332. 49 Kaplan MM, Gandolfo JV, Quaroni EG. An enzyme-linked immunosorbent assay (ELISA) for detecting antimitochondrial antibody. Hepatology 1984; 4: 727– 30. 50 Nagai S, Manns M, Meyer zum Büschenfelde K-H, Dienes HP. Detection of mitochondrial antibodies directed against the primary biliary cirrhosis (M2) antigen by an enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1983; 60: 77– 88. 51 Van de Water J, Cooper A, Surh CD, Coppel R, Danner D, Ansari A, Dickson R, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989; 320: 1377– 1381. 52 Manns M, Meyer zum Büschenfelde K-H. A mitochondrial antigen-antibody system in cholestatic liver disease detected by radioimmunoassay. Hepatology 1982; 2: 1– 7. 53 Frazer IH, Mackay IR, Jordan TW, Whittingham S, Marzuki S. Reactivity of antimitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens. J Immunol 1985; 135: 1739– 1745. 54 Lindenborn-Fotinos J, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen. Hepatology 1985; 5: 763– 769. 55 Mendel-Hartvig I, Nelson BD, Loof L, Totterman TH. Primary biliary cirrhosis: further biochemical and immunological characterization of mitochondrial antigens. Clin Exp Immunol 1985; 62: 371– 379. 56 Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525– 3531. 57 Yeaman SJ, Fussey SPM, Danner DJ, James OFW, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1: 1067– 1069. 58 Van de Water J, Gershwin ME, Leung P, Ansari A, Coppel RL. The autoepitope of the 74 KD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med 1988; 167: 1791– 1799. 59 Fussey SPM, Guest JR, James OFW, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988; 85: 8654– 8658. 60 Surh CD, Danner DH, Ahmed A, Coppel RL, Mackay I, Dickson R, Gershwin ME. Reactivity of primary biliary cirrhosis sera with a alpha-keto acid dehydrogenase dihydrolipoamide acyltransferase, the 52 KD mitochondrial autoantigen. Hepatology 1989; 9: 63– 68. 61 Mackay IR, Gershwin ME. Molecular basis of mitochondrial autoreactivity in primary biliary cirrhosis. Immunol Today 1989; 10: 313– 318. 62 James OFW, Yeaman SJ, Bassendine MF. Molecular aspects of the M2 autoantigens in primary biliary cirrhosis: what a difference a year makes. Hepatology 1989; 10: 247– 251. 63 Van de Water J, Gershwin ME, Leung P, Ansari A, Coppel RL. The autoepitope of the 74 kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med 1988; 167: 1791– 1799. 64 Van de Water J, Fregeau D, Davis P, Ansari A, Danner D, Leung P, Coppel R, et al. Autoantibodies of primary biliary cirrhosis (PBC) recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988; 141: 2321– 2324. 65 Surh CD, Roche TE, Danner DJ, Ansari A, Coppel R, Prindiville T, Dickson ER, Gershwin ME. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. Hepatology 1989; 10: 127– 133. 66 Mutimer DJ, Fussey SPM, Yeaman SJ, Kelly PJ, James OFW, Bassendine MF. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989; 10: 403– 407. 67 Fussey SPM, Yeaman SY, Fittes D, Turner IB, James OWF, Bassendine MF. Pyruvate dehydrogenase (EI) alpha and beta subunits are M2"d" and M2"e" autoantigens in primary biliary cirrhosis (PBC) [Abstract]. J Hepatol 1989; 9 (suppl 1): S33. 68 Yeaman SY. The 2-oxo acid dehydrogenase complexes: recent advances. Biochem J 1989; 257: 625– 632. 69 Stemerowicz R, Hopf U, Möller B, Wittenbrink C, Rodloff A, Reinhardt R, Freudenberg M, et al. Are antimitochondrial antibodies in primary biliary cirrhosis induced by r(rough)mutants of enterobacteriaceae? Lancet 1988; 2: 1166– 1170. 70 Jain S, Markham R, Thomas HC, Sherlock S. Double-stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol 1976; 26: 35– 41. 71 Ruffati A, Arslan P, Floreani A. Nuclear membrane-staining anti-nuclear antibody in patients with primary biliary cirrhosis. J Clin Immunol 1985; 5: 357– 361. 72 Davis P, Read AE. Antibodies to double-stranded (native) DNA in active chronic hepatitis. Gut 1975; 16: 413– 415. 73 Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44: 93– 151. 74 Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet 1965; 2: 878– 879. 75 Wright R. Australia antigen and smooth-muscle antibody in acute and chronic hepatitis. Lancet 1970; 1: 521– 522. 76 Schalm SW, Summerskill WHJ, Gitnick GI, Elveback LR. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis Bs antigen. Gut 1976; 17: 781– 786. 77 Andersen P. Indirect immunofluorescence studies of smooth muscle antibodies. Acta Pathol Microbiol Immunol Scand 1974; 82: 577– 584. 78 Lidman K, Biberfeld G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976; 24: 266– 272. 79 Toh BH. Smooth muscle auto-antibodies and auto-antigens. Clin Exp Immunol 1979; 38: 621– 628. 80 Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973; 15: 331– 344. 81 Manns M, Meyer zum Büschenfelde K-H, Slusarczyk J, Dienes HP. Detection of liver-kidney microsomal autoantibodies by radioimmunoassay and their relation to antimitochondrial antibodies in inflammatory liver diseases. Clin Exp Immunol 1984; 57: 600– 608. 82 Alvarez F, Bernard O, Homberg JC, Kreibich G. Anti-liver-kidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum. J Exp Med 1985; 161: 1231– 1236. 83 Kyriatsoulis A, Manns M, Gerken G, Lohse AW, Ballhausen W, Reske K, Meyer zum Büschenfelde K-H. Distinction between natural and pathological autoantibodies by immunoblotting and densitometric subtraction: liver-kidney-microsomal antibody (LKM) positive sera identify multiple antigens in human liver tissue. Clin Exp Immunol 1987; 70: 53– 60. 84 Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. The major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome p450 dbl. J Clin Invest 1989; 83: 1066– 1072. 85 Zanger UM, Hauri H-P, Loeper J, Homberg J-C, Meyer UA. Antibodies against human cytochrome P-450 dbl in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 8256– 8260. 86 Gueguen M, Meunier–Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the second subfamily. J Exp Med 1988; 168: 801– 806. 87 Beaune PH, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551– 555. 88 Meyer zum Büschenfelde K-H, Miescher PA. Liver specific antigens: purification and characterization. Clin Exp Immunol 1972; 19: 89– 102. 89 Jensen DM, McFarlane IG, Portmann BS, Eddleston ALWF, Williams R. Detection of antibodies directed against a liverspecific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med 1978; 299: 1– 7. 90 Manns M, Meyer zum Büschenfelde K-H, Hess G. Autoantibodies against LSP in acute and chronic liver diseases: studies on organ-, species- and disease-specificity. Gut 1980; 21: 955– 961. 91 McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2: 954– 956. 92 Poralla T, Manns M, Dienes HP, Dippold W, Hütteroth TH, Meyer zum Büschenfelde KH. Analysis of liver-specific protein LSP using murine monoclonal antibodies. Eur J Clin Invest 1987; 17: 360– 367. 93 McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol 1986; 3: 196– 205. 94 Treichel U, Poralla T, Hess G, Manns M, Meyer zum Büschenfelde K-H. Autoantibodies to human asialoglycoprotein receptor (ASGPR) in autoimmune-type chronic hepatitis. Hepatology 1990; 11: 606– 612. 95 Hopf U, Meyer zum Büschenfelde K-H, Arnold W. Detection of a liver membrane autoantibody in HBsAg negative chronic active hepatitis. N Engl J Med 1976; 294: 578– 582. 96 Tage-Jensen U, Arnold W, Dietrichson O, Hardt F, Hopf U, Meyer zum Büschenfelde K-H, Nielson JO. Liver-cell membrane autoantibody specific for inflammatory liver disease. Br Med J 1977; 1: 206– 208. 97 Manns M, Meyer zum Büschenfelde K-H, Hütteroth TH, Hess G. Detection and characterization of liver membrane autoantibodies in chronic active hepatitis by a solid phase radioimmunoassay. Clin Exp Immunol 1980; 42: 263– 272. 98 Gerken G, Manns M, Ramadori G, Poralla T, Dienes HP, Meyer zum Büschenfelde K-H. Liver membrane autoantibodies in chronic active hepatitis: studies on mechanically and enzymatically isolated rabbit hepatocytes. J Hepatol 1987; 5: 65– 74. 99 Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662– 1666. 100 Kyriatsoulis A, Manns M, Gerken G, Lohse AW, Maelicke A, Wessler I, Reske K, et al. Immunochemical characterization of anti-acetylcholine receptor antibodies in primary biliary cirrhosis. J Hepatol 1988; 6: 283– 290. 101 Yamada G, Hyodo I, Tobe K, Mizuno M, Nishihara T, Kobayashi T, Nagashima H. Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelia in primary biliary cirrhosis. Hepatology 1986; 6: 385– 391. 102 Eggink HF, Houthoff HJ, Huitema S, Gips CH, Poppema S. Cellular and humoral immune reactions in chronic active liver disease. I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis. Clin Exp Immunol 1982; 50: 17– 24. 103 Meuer SC, Schlossman SF, Reinherz EL. Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions. Proc Natl Acad Sci USA 1982; 79: 4395– 4399. 104 Sette A, Buus S, Colin S, Smith JA, Miles C, Grey HM. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 1987; 328: 395– 398. 105 Doyle C, Strominger JL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 1987; 330: 256– 259. 106 Long EO. Processing requirements for presentation of antigens to T lymphocytes. Curr Opin Immunol 1988; 1: 98– 102. 107 Beraud E, Reshef T, Vandenbark AA, Offner H, Fritz CH, Bernard D, Cohen IR. Experimental autoimmune encephalomyelitis mediated by T lymphocyte lines: genotype of antigenpresenting cells influences immunodominant epitope of basic protein. J Immunol 1986; 136: 511– 515. 108 Reich E-P, Sherwin RS, Kanagawa O, Janeway CA. An explanation for the protective effect of the MHC class II I-E molecule in murine diabetes. Nature 1989; 341: 326– 328. 109 Mackay IR, Morris PJ. Association of autoimmune active chronic hepatitis with HLA-A1. Lancet 1972; 2: 793– 795. 110 Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI. HLA determinants in chronic liver disease: possible relation to HLA-Dw3 to prognosis. Tissue Antigens 1977; 9: 36– 40. 111 Mackay IR, Whittingham S, Mathews JD, Tail BD. Genetic determinants of autoimmune chronic active hepatitis. Springer Semin Immunopathol 1980; 3: 285– 296. 112 Krawitt EL, Kilby AE, Albertini RJ, Schonfield MS, Chastenay BF, Harper PC, Mickey RM, et al. Immunogenetic studies of autoimmune chronic active hepatitis: HLA, immunoglobulin allotypes and autoantibodies. Hepatology 1987; 7: 1305– 1310. 113 Gores GJ, Moore SB, Fisher LD, Powell FC, Dickson ER. Primary biliary cirrhosis: associations with class II major histocompatibility complex antigen. Hepatology 1987; 7: 889– 892. 114 Van den Oord JJ, Sciot R, Desmet VJ. Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol 1987; 3: 310– 317. 115 Ballardini G, Bianchi FB, Mirakian R, Fallani M, Pisi E, Bottazzo GF. HLA-A, B, C, HLA-C/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol 1987; 70: 35– 46. 116 Spengler U, Pape GR, Hoffmann RM, Johnson FP, Eisenburg J, Paumgartner G, Riethmüller G. Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis. Hepatology 1988; 8: 459– 462. 117 Franco A, Barnaba V, Natali P, Balsano C, Musca A, Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988; 8: 449– 454. 118 Allen PM. Antigen presentation and autoimmunity. Hepatology 1988; 8: 677– 679. 119 Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet 1980; 1: 1166– 1168. 120 Fennell RH Jr. Ductular damage in liver transplant rejection: its similarity to that of primary biliary cirrhosis and graft-versushost disease. Pathol Annu 1981; 16: 289– 294. 121 Demetris AJ, Markus BH, Esquivel C, von Thiel OH, Saidman S, Gordon R, Markova L, et al. Pathologic analysis of liver transplantation for primary biliary cirrhosis. Hepatology 1988; 8: 939– 947. 122 Mori Y, Mori T, Ueda S, Yoshida H, Iesato K, Wakashin Y, Wakashin M, et al. Study of cellular immunity in experimental autoimmune hepatitis in mice: transfer of spleen cells sensitized with liver proteins. Clin Exp Immunol 1985; 61: 577– 584. 123 Araki K, Yamamoto H, Fujimoto S. Studies on the pathogenesis of murine experimental autoimmune active hepatitis: sensitized T cell involvement in its induction. Clin Exp Immunol 1987; 67: 326– 334. 124 Watanabe Y, Kawakami H, Kawamoto H, Ikemoto Y, Masuda K, Takezaki E, Nakanishi T, et al. Effect of neonatal thymectomy on experimental autoimmune hepatitis in mice. Clin Exp Immunol 1987; 67: 105– 113. 125 Brusdeilins M, Hapke C, Huberts HH, Schumacher K. Identification of the apparently lymphocyte-specific human liver-derived inhibitory protein (LIP) as cytoplasmic liver L-arginase. J Immunol 1983; 131: 2427– 2431. 126 Lohse AW, Manns M, Dienes HP, Meyer zum Büschenfelde K-H, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990; 11: 24– 30. 127 Miller J, Smith MGM, Mitchell CG, Reed WD, Eddleston ALWF, Williams R. Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet 1982; 2: 296– 297. 128 Meyer zum Büschenfelde K-H, Knolle J, Berger J. Celluläre Immunreaktionen gegenüber homologen leberspezifischen Antigenen (HLP) bei chronischen Leberentzündungen. Klin Wochenschr 1974; 52: 246– 248. 129 Vento S, Hegarty JE, Bottazzo GF, Macchia E, Williams R, Eddleston ALWF. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1981; 1: 1200– 1204. 130 Vento S, O'Brien CJ, McFarlane BM, McFarlane IG, Eddleston ALWF, Williams R. T-lymphocyte sensitization to hepatocyte antigens in autoimmune chronic active hepatitis and primary biliary cirrhosis: evidence for different underlying mechanisms and different antigenic determinants as targets. Gastroenterology 1986; 91: 810– 817. 131 Thestrup-Pedersen K, Ladefoged K, Andersen P. Lymphocyte transformation test with liver-specific protein and phytohaemagglutinin in patients with liver disease. Clin Exp Immunol 1976; 24: 1– 8. 132 Hoffmann RM, Pape GR, Rieber P, Eisenburg J, Dörmann J, Spengler U, Paumgartner G, et al. Cytolytic T cell clones derived from liver tissue of patients with chronic hepatitis B. Eur J Immunol 1986; 16: 1635– 1638. 133 Meuer SC, Moebius U, Manns M, Dienes HP, Ramadori G, Hess G, Hercend T, et al. Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis. Eur J Immunol 1988; 18: 1447– 1452. 134 Thomas HC, Holden R, Jones JV, Peacock DB. Immune response to X174 in man: primary and secondary antibody production in primary biliary cirrhosis. Gut 1976; 17: 844– 848. 135 Surh CD, Cooper AE, Coppel RL, Leung P, Ahmed A, Dickson R, Gershwin ME. The predominance of IgG3 and IgM isotype antimitochondrial autoantibodies against recombinant fused mitochondrial polypeptide in patients with primary biliary cirrhosis. Hepatology 1988; 8: 290– 295. 136 Bahn AK, Dienstag JL, Wands JR, Schlossman SF, Reinherz EL. Alterations of T-cells subsets in primary biliary cirrhosis. Clin Exp Immunol 1982; 47: 351– 8. 137 Miller KB, Elta GH, Rudders RA, Kaplan MM. Lymphocyte subsets in primary biliary cirrhosis. Ann Intern Med 1984; 100: 385– 387. 138 Frazer IH, Mackay IR. T-lymphocyte subpopulations defined by two sets of monoclonal antibodies in chronic active hepatitis and systemic lupus erythematosus. Clin Exp Immunol 1982; 50: 107– 114. 139 Mariani E, Facchini A, Miglio F, Stefanini F, Mazzetti M, Leupers T, Gasbarrini G, et al. Analysis with OKT monoclonal antibodies of T-lymphocytes subsets present in blood and liver of patients with chronic active hepatitis Liver 1984; 4: 22– 28. 140 Thomas HC, Brown D, Labrooy J, Epstein O. T-cell subsets in autoimmune and HBV induced chronic liver disease: a review of the abnormalities and effects of treatment. Liver 1982; 2: 266– 269. 141 Thomas HC, Freni M, Sanchez-Tapias J, DeVilliers D, Jain S, Sherlock S. Peripheral blood lymphocyte populations in chronic liver disease. Clin Exp Immunol 1976; 26: 222– 227. 142 Nonomura A, Tanino M, Kurumaya H, Ohta G, Kato Y, Kobayashi K. Disordered immunoregulatory functions in patients with chronic active hepatitis. Clin Exp Immunol 1982; 47: 595– 605. 143 Tremolada F, Fattovich G, Panebianco G, Ongaro G, Realdi G. Suppressor cell activity in viral and non-viral chronic active hepatitis. Clin Exp Immunol 1980; 40: 89– 95. 144 James SP, Elson CO, Jones EA, Strober W. Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis. Gastroenterology 1980; 79: 242– 54. 145 Zetterman RK, Woltjen JA. Suppressor cell activity in primary biliary cirrhosis. Dig Dis Sci 1980; 25: 104– 107. 146 James SP, Elson CO, Waggoner JG, Jones EA, Strober W. Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis. J Clin Invest 1980; 66: 1305– 1310. 147 Noui-Aria KT, Hegarty JE, Alexander GJM, Eddleston ALWF, Williams R. Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. N Engl J Med 1982; 307: 1301– 1304. 148 Hirofuij H, Kakumu S. Fuji A, Ohtani Y, Murase K, Tahara H. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells. Clin Exp Immunol 1987; 68: 348– 356. 149 De Fernandez MA, Clark A, Triger DR. Neutrophil phagocytic and bactericidal function in primary biliary cirrhosis and other chronic liver diseases. Clin Exp Immunol 1987; 67: 655– 661. 150 Alpert SD, Koide J, Takada S, Engleman EG. T cell regulatory disturbances in the rheumatic diseases. Immunol Rheum Dis 1987; 13: 431– 445. 151 Lindor KD, Wiesner RH, Dickson ER, Homburger HA. The autologous mixed lymphocyte reaction in primary biliary cirrhosis: analysis of activation and blastogenesis of autoreactive T lymphocytes. Hepatology 1988; 8: 1555– 1559. 152 Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JMT, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984; 25: 133– 137. Citing Literature Volume12, Issue2August 1990Pages 354-363 ReferencesRelatedInformation
Referência(s)